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Abstract
The aim of this multicentre, longitudinal study was to determine salivary changes in relation to oral mucositis (OM) in
multiple myeloma patients following high-dose melphalan and autologous hematopoietic stem cell transplantation (ASCT).
Unstimulated and stimulated whole-mouth saliva samples (UWS and SWS) were collected before ASCT, 1×/wk during the
hospitalisation phase, and 3 and 12 months post-ASCT. During the hospitalisation period OM was scored 3×/wk (WHO
system). Flow rate, pH, total protein concentration (Nanodrop), albumin, lactoferrin, neutrophil defensin-1 (HNP1), total IgA
and S100A8/A9 (ELISA) were determined. Mixed models were used to evaluate differences between ulcerative (u)OM (≥2
WHO, n= 20) and non-uOM (n= 31) groups. Until 18 days after ASCT, flow rate, pH, total IgA and HNP1 levels
decreased in UWS and/or SWS, while log lactoferrin levels were significantly increased (UWS: p= 0.016 95% CI [0.36,
3.58], SWS: p < 0.001 95% CI [1.14, 3.29]). Twelve months post-ASCT, salivary protein levels were similar to baseline
except for log total IgA, which was higher (UWS: p < 0.001 95% CI [0.49, 1.29], SWS: p < 0.001 95% CI [0.72, 1.45]). No
differences between uOM and non-uOM groups were observed. Changes in salivary proteins indicated an inflammatory
reaction in salivary glands coinciding with mucosal and systemic reactions in response to high-dose melphalan.
Introduction
A common and most debilitating complication of high-dose
melphalan (HDM) before autologous hematopoietic stem
cell transplantation (ASCT) is oral mucositis (OM),
clinically characterised by erythema, oedema and ulcera-
tions [1, 2]. Patients’ symptoms include pain and a dry
mouth [2]. Although local vasoconstriction by ice chips
(cryotherapy) during the infusion of melphalan significantly
These authors contributed equally: M.C.D.N.J.M. Huysmans, F.
R. Rozema
* S. J. M. van Leeuwen
Stephanie.vanLeeuwen@radboudumc.nl
1 Radboud Institute for Health Sciences, Department of Dentistry,
Radboud University Medical Center, Nijmegen, The Netherlands
2 Centre for Host Microbiome Interactions, Faculty of Dentistry,
Oral & Craniofacial Sciences, King’s College, London, UK
3 Department of Oral Medicine, Academic Centre for Dentistry
Amsterdam, University of Amsterdam and VU University,
Amsterdam, The Netherlands
4 Department of Preventive Dentistry, Academic Centre for
Dentistry Amsterdam, University of Amsterdam and VU
University, Amsterdam, The Netherlands
5 Radboud Institute for Health Sciences, Department of
Hematology, Radboud University Medical Center, Nijmegen, The
Netherlands
6 Department of Hematology, Amsterdam UMC, University of
Amsterdam, Amsterdam, The Netherlands
7 Department of Oral Medicine, Atrium Health’s Carolinas Medical
Centre, Charlotte, NC, USA
8 Department of Oral Microbiology and Immunology, Institute of
Odontology, The Sahlgrenska Academy, University of
Gothenburg, Gothenburg, Sweden
9 Department of Oral and Maxillofacial Surgery, Amsterdam UMC,
University of Amsterdam, Amsterdam, The Netherlands
Supplementary information The online version of this article (https://
doi.org/10.1038/s41409-020-01185-7) contains supplementary















reduces the incidence of OM, it is still present in up to 44%
of patients [3].
Saliva, a mixture of water, ions and proteins, is mainly
produced by three pairs of major salivary glands: the parotid,
submandibular and sublingual glands. The contribution of
each gland is different between unstimulated and stimulated
saliva. In stimulated saliva, the parotid gland is more active
resulting in a more watery saliva [4]. Saliva has several
functions including lubrication and protection, mainly related
to proteins [4]. Mucins play a major role in lubrication, while
lactoferrin, defensins and IgA have antimicrobial activities
and are important for the protective function [5].
IgA is the main immunoglobulin found in saliva, and it is
responsible for the humoral immune response at the oral
mucosa [6]. Binding of (secretory) IgA limits mucosal colo-
nisation and subsequent invasion of microorganisms [6].
Polymorphonuclear leucocytes (PMNs) and oral keratinocytes
also play a role in the innate immunity of the oral mucosa
[6, 7]. Since the azurophilic granules of PMNs are the only
source of neutrophil defensin-1 (HNP1) [8], it could be used
as a marker of PMNs in saliva. Another product in the
granules of PMNs and oral keratinocytes found in saliva is
S100A8/A9 (or calprotectin) [9, 10].
As a consequence of the chemotherapy and/or radio-
therapy before an autologous and allogeneic SCT, changes
in salivary flow rate and salivary proteins have been
reported [11]. Decreasing trends were reported for salivary
flow rate and salivary IgA levels up to 1 month after
autologous and allogeneic SCT, while albumin and lacto-
ferrin levels were increased in the first weeks and up to 1
and 6 months, respectively, after autologous and allogeneic
SCT [11–14].
A low salivary flow rate was identified as a risk factor for
OM in patients receiving the chemotherapeutic agent 5-
fluorouracil [15]. Whether changes in salivary proteins are
associated with OM and to what extent is still unknown.
Therefore, the aim of this longitudinal, multicentre study was
to determine salivary changes in relation to OM in multiple
myeloma (MM) patients following HDM and ASCT.
Materials and methods
Study population
This study was part of the Ora-stem study, an international,
prospective, longitudinal, multicentre study to investigate
oral problems after conditioning therapy and ASCT [16]. In
the present study (funded by Dutch Cancer Society, ACTA
2014-7468; trial register NTR5760), 51 MM patients treated
with ASCT following HDM (200 mg/m2) were included in
both Amsterdam University Medical Centre (location
Academic Medical Centre (AMC)) or Radboud University
Medical Centre (Radboudumc) Nijmegen between Sep-
tember 2015 and March 2017. According to a power ana-
lysis using a non-parametric longitudinal data analysis
equation (difference in proportion 0.21, α of 0.05, 6 sample
moments per patient, correlation between follow-up mea-
surements 0.3 and 50% development of severe OM),
48 MM patients needed to be included to ensure a power of
0.80. Patients were excluded when they were not able to
understand the provided information, a second SCT was
planned in advance, the time before the ASCT was too short
to consider study participation or when a transfer to another
hospital was planned shortly after ASCT. Ethical approval
was obtained (NL52117.018.15) and the study was con-
ducted according to GCP guidelines and the World Medical
Association Declaration of Helsinki. Before participating,
all patients signed informed consent.
To prevent OM, most patients self-administered cryo-
therapy during the infusion of HDM. Cryotherapy was
started 5–10 min before HDM infusion and was stopped
directly after infusion (AMC) or 30 min after infusion
(Radboudumc), according to local practice standards.
Compliance with the cryotherapy protocol was monitored,
but not enforced. Patients treated at the AMC received
HDM infused over 2 days (30 min, 100 mg/m2 each IV),
while patients treated at the Radboudumc received one day
infusion of HDM (1 h, 200 mg/m2 IV). Safety controls and
vital signs monitoring was standard practice including
routine laboratory measurements (including blood counts
and renal and liver chemistry).
Saliva collection and OM scoring
Unstimulated and stimulated whole-mouth saliva (UWS and
SWS) samples were collected before ASCT during the pre-
transplantation dental evaluation (baseline), once a week
during the hospitalisation/ASCT phase and 3 and 12 months
after ASCT during follow-up dental check-ups. Baseline
characteristics were collected during the pre-transplantation
dental evaluation. OM was scored using the WHO scoring
system 3 times a week during the hospitalisation period (all
patients with a score of 2 or above were considered as
having ulcerative OM (uOM)) [17]. Before saliva collection
patients were asked to refrain from eating and drinking for
1 h. UWS was collected without any stimulation and SWS
was collected by chewing on a neutral chewing gum base as
previously described [12]. After collection, pH was mea-
sured and flow rate was determined using a scale
(assumption: 1 ml of saliva is 1 g) [12].
Salivary analysis
Total protein concentration was determined by absorbance
(280 nm, Nanodrop spectrophotometer) for all samples and
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by bicinchoninic acid assay (BCA) for some of the samples
(according to manufacturer’s protocol, PierceTM BCA pro-
tein assay kit, Thermo Scientific, USA). Albumin, lacto-
ferrin, HNP1, secretory IgA (sIgA), S100A8/A9 and total
IgA concentrations were determined by enzyme-linked
immunosorbent assay (ELISA). Albumin, HNP1 and
S100A8/A9 levels were determined in a selection of
patients with the highest number and volumes of samples
(14 patients of each centre: 7 uOM and 7 non-uOM). For
secretory IgA, 3 uOM and 4 non-uOM patients were
selected with high total IgA concentrations. All details
regarding the ELISAs and the patient characteristics of the
subset compared to the entire study population are descri-
bed in Supplementary File 1.
Statistical analysis
For the changes in protein concentrations over time, all
individual samples were allocated to one of 7 time periods
based on day of collection (day 0 is day of ASCT): baseline
(base), days −4–0, days 1–5, days 6–11, days 12–18,
3 months (3 M), and 12 months (12 M). Patients were
divided into two groups with or without ulcerative OM
(uOM and non-uOM). Graphs were made using GraphPad
Prism (version 5.03) and statistical analyses were performed
in R (version 3.5.1), where p < 0.05 was considered statis-
tically significant. Because of non-normal distributions log
transformation was applied for the concentrations of total
protein, albumin, total IgA, lactoferrin and HNP1. For
salivary flow rate, only data from Radboudumc patients
were analysed (at the AMC a less sensitive scale was
operational). A flow rate of 0 ml/min was recorded if there
was no saliva production in 5 min.
Differences between the uOM and non-uOM group was
determined at baseline using unpaired T tests and for
combined time points after baseline using multi-level linear
models with random intercepts. Changes in salivary flow
rate and pH, and in salivary protein concentrations were first
evaluated using graphs. Observed changes over relevant
time periods, were subsequently analysed for statistical
significance using multi-level regression analysis with ran-
dom intercepts with OM and time as independent variables.
For HNP1 tobit regression was used to analyse outcomes
with observations outside detection limits. For the tobit
regression, bootstrapping with 1000 replicates was applied
to obtain 95% confidence intervals.
Results
Study population and saliva collection
In this study, 51 MM patients (53% male) with a median
age of 58 years (range 33–69) were included, of which 39%
developed uOM (44% AMC/ACTA and 33% Radbou-
dumc) during ASCT phase (Table 1). Peak OM scores were
seen between days 6 and 11 in both centres. The patient
group from the AMC contained more males, but the mel-
phalan dose in mg/kg and creatinine levels before ASCT
were similar in both centres (Table 1).
The baseline saliva samples were collected at a median
of 36 days (range −124 to −4) before ASCT. At baseline,
patients had already been treated with different che-
motherapy cycles (VCD (bortezomib, cyclophosphamide
and dexamethasone); cyclophosphamide; or lenalidomide
and dexamethasone). The start date of the last chemother-
apy cycle was at a median of 15 days before the baseline
measurements (range 0–114; Table 1). The 3- and
12 months follow-up visits took place at a median of 105
(range 75–170) and 375 (range 331–506) days after ASCT,
respectively.
Although saliva collection was attempted at all time
points, some samples were missed during the hospitalisation
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Fig. 1 Salivary flow rate over time in uOM and non-uOM groups.
Median ± IQR for unstimulated whole-mouth saliva (UWS) (a) and
stimulated whole-mouth saliva (SWS) (b) flow rate over time in the
ulcerative oral mucositis (uOM) and non-uOM groups. Numbers in the
graphs represent the number of samples at the different time points in
the uOM and non-uOM groups.
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saliva (due to nausea (9%) or no saliva production (3%);
Supplementary File S2). UWS and/or SWS samples were
collected at a median of 5 different time points per patient
(range 2–6) in both centres.
Impact of OM
Salivary flow rate and concentrations of different salivary
proteins were generally not different between the uOM and
non-uOM groups (Supplementary File S3, Figs. 1–4).
Salivary changes over time
SWS flow rate and UWS and SWS pH were significantly
decreased up to day 18 compared to baseline levels (see
Fig. 1 and Supplementary File S4 for visual presentations
and Table 2 for p values and 95% CI intervals). Twelve
months after ASCT, UWS and SWS flow rate and UWS pH
were returned to baseline levels (Table 2). Due to low-
salivary flow rates and therefore low saliva volumes for
some patients, total protein concentrations of all samples
were determined using a low volume spectrophotometer
(Nanodrop). Although, total protein concentrations
were generally higher using Nanodrop, time-dependent
trends were similar for Nanodrop and BCA assay (Sup-
plementary File S5). No changes over time were seen for
UWS total protein concentrations, while in SWS the graph
showed an increase at 1–5 days after ASCT (Supplementary
File S5).
High variation in albumin concentrations were seen in
UWS and SWS with no clear changes over time. Only in the
uOM group, the graph showed a small increase at days 6–11
in UWS (Supplementary File S6).
IgA
Salivary total IgA concentrations were significantly lower in
the second and third week after ASCT (days 6–18) com-
pared to the first week (days −4–5), while 12 months after
ASCT, total IgA concentrations were higher compared to












Mean ± SD 57.5 ± 7.3 57.9 ± 8.4 57.0 ± 6.2 58.8 ± 8.6 56.7 ± 6.5
Median 58 62 56 61 56
Range 33–69 33–69 42–69 33–69 42–66
Gender
Male (%) 27 (52.9) 17 (63.0) 10 (41.7) 10 (50.0) 17 (54.8)
Cryotherapy
Cryotherapy used (n (%)) 40 (78.4) 27 (100) 13 (54.2) 17 (85.0) 23 (74.2)
Creatinine levels before ASCT (days
−3–0) (µmol/l)
Mean ± SD 74.6 ± 22.9 73.6 ± 24.9 75.7 ± 21.0 84.7 ± 30.6 68.1 ± 13.1
Median 68 66 70.5 78.5 67
Range 45–145 45–145 49–129 45–145 49–94
Days between start of last
chemotherapy cycle and
baseline sample
Mean ± SD 25.2 ± 26.8 23.6 ± 34.5 27.1 ± 14.2 32.6 ± 35.4 20.5 ± 18.5
Median 15 10 19.5 18.5 15
Range 0–114 0–114 9–58 0–114 1–95
Melphalan dose (mg/kg)
Mean ± SD 5.00 ± 0.45 5.01 ± 0.49 4.98 ± 0.41 4.90 ± 0.40 5.06 ± 0.48
Median 4.96 5.00 4.92 4.86 5.06
Range 4.12–5.87 4.15–5.82 4.12–5.87 4.12–5.61 4.15–5.87
Type M-protein (n (%))
IgA 14 (27.5) 9 (33.3) 5 (20.8) 6 (30.0) 8 (25.8)
IgG 23 (45.1) 12 (44.4) 11 (45.8) 6 (30.0) 17 (54.8)
IgM 1 (2.0) 0 1 (4.2) 0 1 (3.2)
Others 13 (25.5) 6 (22.2) 7 (29.2) 8 (40.0) 5 (16.1)
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baseline (see Fig. 2 for visual presentation and Table 2 for
p values and 95% CI intervals) and highly variable. To
determine the salivary gland specific contribution of the
total IgA concentration, secretory IgA (sIgA) concentrations
were determined for a subset of patients. In general, sIgA
concentrations were lower than total IgA concentrations but
showed the same time-dependent changes. The very high
values for total IgA at baseline, 3 and 12 months after
ASCT were not found in the sIgA concentrations (Supple-
mentary File S7).
Excluding the patients with an IgA type MM from the
analysis resulted in similar changes over time. Also high
levels were still present in the remaining patients, suggest-
ing that the high levels measured were not derived from the
MM. To correct for the total IgA levels that may be lost
during centrifugation, total IgA concentrations were deter-
mined in the pellet fraction. No differences were found
between pellet and supernatant total IgA concentrations
over time (data not shown).
Antimicrobial peptides (lactoferrin, HNP1 and
S100A8/A9)
A significant increase in lactoferrin concentrations in UWS
(effect size 2.01) and SWS (effect size 1.14) was found
during the hospitalisation period (see Fig. 3 and Table 2).
Twelve months after ASCT, UWS and SWS lactoferrin
returned towards baseline concentrations.
Lactoferrin in saliva is derived from the salivary glands
and PMNs [12, 18]. To determine the proportion derived
from the PMNs, two other salivary antimicrobial peptides
derived from PMNs (HNP1 and calprotectin (S100A8/A9))
were studied over time for a subset of the samples. HNP1
concentrations were significantly lower between days 6–18
after ASCT compared to days −4–5 after ASCT in UWS
and SWS (effect size −3.42 and −3.09, respectively, see
Fig. 4a, b and Table 2). At days 6–11, the HNP1 con-
centration was below the detection limit in saliva for part of
the samples, and while a small increase was seen at
Base -4 - 0 1 - 5 6 - 11 12 - 18 3 M 12 M
Time after ASCT
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Fig. 3 Salivary lactoferrin concentration over time in OM and
non-uOM groups. Median ± IQR lactoferrin concentration in unsti-
mulated whole-mouth (UWS) (a) and stimulated whole-mouth saliva
(SWS) (b) over time in the ulcerative oral mucositis (uOM) and non-
uOM groups. Numbers in the graph represent the number of samples at
the different time points in the uOM and non-uOM groups.
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Fig. 2 Salivary total IgA concentration over time in uOM and non-
uOM groups. Median ± IQR total IgA concentration in unstimulated
whole-mouth saliva (UWS) (a) and stimulated whole-mouth saliva
(SWS) (b) over time in the ulcerative oral mucositis (uOM) and non-
uOM groups. Numbers in the graph represent the number of samples at
the different time points in the uOM and non-uOM groups.
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3 months in HNP1 concentration in UWS and SWS,
baseline levels were only reached at 12 months (Fig. 4a, b).
A similar decreasing trend reaching 0 between days 5 and
11 after ASCT was seen in the number of PMNs in blood in
the uOM and non-uOM group, while morning body tem-
perature showed an increasing trend during these days
(Supplementary File S8). The S100A8/A9 concentrations
fluctuated in UWS and SWS (Fig. 4c, d).
Discussion
The aim of this study was to determine salivary changes in
relation to OM in MM patients treated with HDM followed
by ASCT. In the second and third weeks after ASCT,
increased lactoferrin concentrations were observed together
with decreased concentrations of total IgA, HNP1, pH and
diminished UWS and SWS flow rates compared to baseline.
Twelve months after ASCT all proteins returned to baseline
concentrations, except for total IgA, where concentrations
were higher at 12 months after ASCT. No differences were
found between the uOM and non-uOM groups with respect
to changes in salivary flow rate or salivary protein
concentrations.
The decreased concentrations of total IgA, HNP1, pH
and diminished UWS and SWS flow rate found in this
study, indicate impaired oral mucosal immunity during peak
OM scores [11–13]. The decreased total IgA concentration
also signifies reduced antimicrobial activity in saliva, pos-
sibly compensated to some degree by increased lactoferrin
concentrations [12]. There have been indications that
glandular inflammation may lead to higher lactoferrin
concentrations in saliva. Increased concentrations of lacto-
ferrin were reported during chronic recurrent parotitis and
Sjögren’s syndrome [19–22]. In those studies, the tenfold
elevation in lactoferrin concentration, which was thus much
higher than observed in our study, likely originated from
infiltrating PMNs in addition to increased glandular secre-
tion as a result of the inflammatory reaction [19, 21].
In our study, twofold elevated lactoferrin levels were
observed during peak OM scores and neutropenia, sugges-
tive of glandular secretion of lactoferrin. HNP1, derived
from PMNs granules [12, 18], could also not be detected in
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Fig. 4 Salivary HNP1 and S100A8/A9 concentration over time in
uOM and non-uOM groups. Median ± IQR HNP1 (neutrophil
defensin-1) (a+ b) and S100A8/A9 (c+ d) concentration in unsti-
mulated whole-mouth saliva (UWS) (a+ c) and stimulated whole-
mouth saliva (SWS) (b+ d) over time in the ulcerative oral mucositis
(uOM) and non-uOM groups. Numbers in the graph represent the
number of samples at the different time points in the uOM and non-
uOM groups. Numbers between brackets represent the amount of
samples with readings below (−) or above (+) the detection limit.
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derived from the PMNs in the crevicular fluid is therefore
expected to be negligible [23]. S100A8/A9, another com-
ponent of PMNs granules fluctuated over time. This could
be due to the inducible release of S100A8/A9 by oral ker-
atinocytes [9, 10]. In lichen planus, candidiasis and other
inflammatory diseases of the oral mucosa increased levels
of S100A8/A9 were reported [24]. The up-regulation of
S100A8/A9 by oral keratinocytes was insufficient to com-
pensate for the considerable reduction in S100A8/A9 levels
in UWS and SWS by PMNs during neutropenia.
Elevated lactoferrin might be protective for salivary
glands, due to the scavenger and regulatory effects of lac-
toferrin on cell growth and differentiation as found in irra-
diated glands [25]. Lactoferrin also inhibits the pro-
Table 2 Results of multi-level analysis of pH, flow rate, total IgA, HNP1 and lactoferrin concentration.
UWS SWS
Effect 95% CI p Effect 95% CI p
pH (ASCT period)
Intercept 5.90 [5.83, 5.98] <0.001 6.27 [6.11, 6.42] <0.001
OMa (yes= 1, no= 0) −0.02 [−0.14, 0.11] 0.806 0.10 [−0.15, 0.35] 0.429
Timeb (base= 0, 0–18= 1) −0.01 [−0.01, −0.004] <0.001 −0.01 [−0.02, −0.01] <0.001
pH (base/12 M)
Intercept 6.20 [6.09, 6.32] <0.001 6.94 [6.78, 7.10] <0.001
OMa (yes= 1, no= 0) 0.02 [−0.13, 0.18] 0.768 0.26 [0.02, 0.49] 0.032
Timeb (base= 0, 12 M= 1) −0.01 [−0.13, 0.11] 0.824 −0.21 [−0.38, −0.04] 0.013
Flow rate (ASCT period)
Intercept 0.23 [0.17, 0.28] <0.001 0.63 [0.47, 0.78] <0.001
OMa (yes= 1, no= 0) −0.06 [−0.15, 0.04] 0.250 0.03 [−0.23, 0.29] 0.830
Timeb (base= 0, 0–18= 1) −0.001 [−0.002, 0.000] 0.257 −0.008 [−0.01, −0.004] <0.001
Flow rate (base/12 M)
Intercept 0.29 [0.21, 0.37] <0.001 1.03 [0.80, 1.26] <0.001
OMa (yes= 1, no= 0) −0.08 [−0.21, 0.05] 0.242 0.29 [−0.09, 0.66] 0.137
Timeb (base= 0, 12 M= 1) 0.01 [−0.06, 0.07] 0.784 −0.09 [−0.26, 0.08] 0.304
Total IgAc (ASCT period)
Intercept 4.03 [3.56, 4.50] <0.001 3.61 [3.12, 4.09] <0.001
OMa (yes= 1, no= 0) 0.06 [−0.64, 0.76] 0.865 0.04 [−0.70, 0.78] 0.913
Timeb (−4–5= 0, 6–18= 1) −0.52 [−0.92, −0.12] 0.011 −0.76 [−1.09, −0.41] <0.001
Total IgAc (base/12 M)
Intercept 5.45 [5.03, 5.86] <0.001 4.81 [4.40, 5.22] <0.001
OMa (yes= 1, no= 0) −0.07 [−0.65, 0.51] 0.815 −0.23 [−0.83, 0.36] 0.435
Time (base= 0, 12 M= 1) 0.89 [0.49, 1.29] <0.001 1.08 [0.72, 1.45] <0.001
HNP1c, d
Intercept −0.36 [−1.41, 0.68]e 0.496 0.12 [−0.78, 0.91]e 0.748
OMa (yes= 1, no= 0) 0.05 [−1.42, 1.68]e 0.974 0.49 [−0.63, 1.78]e 0.430
Timeb (−4–5= 0, 6–18= 1) −3.42 [−5.08, −1.91]e <0.001 −3.09 [−4.40, −1.76]e <0.001
Lactoferrinc
Intercept 1.14 [−0.48, 2.75] 0.167 0.16 [−0.94, 1.26] <0.001
OMa (yes= 1, no= 0) −0.37 [−2.46, 1.71] 0.727 0.90 [−0.55, 2.35] 0.224
Timeb (base= 0, 1–18= 1) 2.01 [0.36, 3.58] 0.016 1.14 [1.14, 3.29] <0.001
Bold: significant differences over time.
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inflammatory cytokines IL-1, IL-6 and TNF-α [26, 27],
which play an important role in the pathogenesis of OM
[28]. Lactoferrin has been investigated for use as a pre-
ventive agent against infections and inflammatory compli-
cations in ASCT patients with unreported success [29, 30].
However, topical administration of bovine lactoferrin on
ulcerations in chemotherapy-induced mucositis in hamsters
resulted in more and larger ulcerations compared to the
control group (treated with bovine serum albumin) [31].
The inflammatory response to HDM is gradually resolved
during the hospitalisation period. In an animal model, the
cytotoxic effects of 5-fluorouracil in the submandibular and
sublingual glands were decreasing 10 days after che-
motherapeutic administration [32]. This fits with the return
of lactoferrin to baseline levels at 12 months after autologous
SCT. The previously reported increase in lactoferrin,
β2-microglobulin and secretory leucocyte protease inhibitor
at 6 months after allogeneic SCT is probably a result of
lymphocytic infiltration of the salivary glands due to Graft-
versus-Host Disease after allogeneic SCT [11, 14].
Total IgA levels were higher at 12 months after ASCT
compared to baseline, but were comparable with the expected
sIgA levels in UWS in healthy individuals [33]. This indi-
cates that total IgA levels were already relatively low at
baseline, likely as a result of the impaired IgA production by
the plasma cells due to the various chemotherapy cycles in
the work-up before ASCT [34, 35], with further reduction
during the second and third weeks after ASCT due to HDM
effects. Increasing levels of total IgA and sIgA at 3 and
12 months after ASCT, reflect the recovery of sIgA produc-
tion by the salivary glands when the IgA production of the
plasma cells is restored [34, 35]. Although the various che-
motherapy cycles before baseline also might have induced
some damage to the salivary glands resulting in xerostomia
and salivary hypofunction [36], total IgA levels were low due
to these chemotherapies affecting the number of plasma cells.
Contrary to expectation, we found no differences
between levels of salivary proteins and/or salivary flow rate
between uOM and non-uOM patients. We only identified
impaired protective functions of saliva by decreased levels
of total IgA, HNP1, pH and diminished salivary flow rate
and a local glandular inflammatory reaction to HDM by
increased lactoferrin concentration. The increased levels of
lactoferrin coincided with a systemic inflammatory reaction
indicated by neutropenia and increasing body temperature
(Fig. 5) [37]. These biological changes were similar
between uOM and non-uOM patients, indicating a general
inflammatory reaction induced by HDM.
The course of OM found in this study was consistent
with a previous report [38]. However, prevalence of uOM
was lower, possibly due to cryotherapy [3, 12]. The role of
cryotherapy in our study, however, is unclear as the centre
with the lowest uOM prevalence also had the lowest cryo-
therapy compliance (54% vs. 100%). Melphalan dose in
mg/kg and creatinine levels in both centres were similar.
There was only a small difference in the duration of HDM
administration in the low vs. high uOM prevalence centre (1
vs. 2 days) and duration of cryotherapy (stopped 30 min
Systemic reaction


















Fig. 5 Schematic overview of the hypothesised effects of the
inflammatory reactions induced by high-dose melphalan. High-
dose melphalan induces a systematic reaction, a mucosal reaction and
a reaction in the salivary glands in all patients (uOM and non-uOM).
The systemic reaction includes the increase in body temperature and
decrease in the leucocytes/neutrophil counts in blood. The mucosal
reaction includes oral mucositis and a decreased oral mucosal defence
by decreased levels of salivary flow rates, IgA and neutrophil defensin-
1 concentrations. Those reactions coincide with the inflammatory
reaction in the salivary glands leading to increased lactoferrin con-
centrations in saliva.
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after infusion vs. directly after infusion) that is not of
clinical significance.
In conclusion, this study highlights changes in salivary
proteins that indicate an inflammatory reaction in the sali-
vary glands coinciding with mucosal and systemic reactions
in response to HDM in MM patients, with similar reactions
in uOM and non-uOM patients (Fig. 5).
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